Kimberly-Clark completes Kenvue acquisition, creating consumer health leader

Kimberly-Clark (KMB) has completed its acquisition of Kenvue, creating a combined global consumer health and wellness company. Kenvue shareholders receive $3.50 in cash and 0.14625 KMB shares per KVUE share. Kenvue stock ceased trading on the NYSE as of the market open on November 2, 2026. The combined company now operates four business segments and holds 10 billion-dollar brands, including Huggies, Tylenol, and Neutrogena. Kimberly-Clark reaffirmed anticipated run-rate synergies of approximately $2.1 billion, with $1.9 billion in cost synergies expected within three years and $500 million in incremental profit from revenue synergies, partially offset by $300 million in reinvestment, within four years. Three Kenvue board members have joined the Kimberly-Clark board, which now has 13 directors.